Skip to main content



Status: One Wales interim decision

Using the agreed starting and stopping criteria, sorafenib can be made available within NHS Wales for maintenance treatment following allogeneic stem cell transplantation for acute myeloid leukaemia associated with a FLT3 ITD mutation.

The risks and benefits of the off-label use of sorafenib for this indication should be clearly stated and discussed with the patient to allow informed consent.

In February 2022 OWMAG recommended this treatment in NHS Wales, in May 2023 there was a review of the recommendation. OWMAG found nothing new that effects the original decision.

Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available.

 One Wales Interim Decision with start stop criteria and evidence review. Sorafenib for AML Maintenance (OW18). 2023. (PDF, 117Kb)

Medicine details

Medicine name Sorafenib
Formulation 200 mg film-coated tablet
Reference number OW18

Maintenance treatment following allogeneic haematopoietic cell transplantation for acute myeloid leukaemia associated with a FLT3-ITD mutation

Company Various
BNF chapter Malignant disease & immunosuppression
Submission type One Wales
Status One Wales interim decision
Advice number OW18
Date of issue 14/04/2022
Date of last review 21/06/2023
Follow AWTTC: